Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06006689
Other study ID # TSL-TCM-QSYQDW-DKD-?
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 4, 2023
Est. completion date September 1, 2025

Study information

Verified date March 2024
Source Tasly Pharmaceutical Group Co., Ltd
Contact Rui Liu
Phone 022-86343626
Email liurui2@tasly.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy and Safety of QiShen YiQi Dripping Pills in the treatment of Diabetic Kidney Disease (syndrome of Qi deficiency with blood stasis)


Recruitment information / eligibility

Status Recruiting
Enrollment 228
Est. completion date September 1, 2025
Est. primary completion date September 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Man or woman between 18-75 years-old - Subjects with type 2 diabetes mellitus - Subjects with a clinical diagnosis of diabetic kidney disease - eGFR= 45 mL/min/1.73 m2 - UACR = 30 mg/g but = 300 mg/g - Conformed to the TCM syndrome differentiation standard of chronic heart failure syndrome of Qi deficiency and blood stasis - Received Steady dose of ACEI or ARB therapy for chronic heart failure at least 2 weeks before receiving investigational drug - Abide by the experimental protocol and cooperate with the data collection according to the researcher's judgment Exclusion Criteria: - Subjects with type 1 diabetes mellitus or other specific types of diabetes - Acute complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemia occurred in the past 3 months - HbA1c =8.5% or fasting blood glucose >11 mmol/L - Urinary sediment indicates "active" glomerulogenic hematuria - Subjects have been clinically confirmed cases of primary glomerular disease, secondary glomerular disease other than DKD or other systemic diseases - The presence of uncontrolled hypertension, systolic blood pressure =160mmHg and/or diastolic blood pressure =100mmHg or Hypotension with a systolic blood pressure <90mmHg and/or a diastolic blood pressure <60mmHg - ALT or AST> 2 times the upper limit of normal - Serum potassium> the upper limit of normal - Patients with unstable basic treatment for lowering blood glucose and blood lipids within the past 3 months, and patients with unstable basic treatment for lowering blood pressure within the past 1 month (changing the type of drugs, such as changing the ß-receptor blockers to calcium ion antagonists, etc.) - Take the following medications within the last 2 weeks:a. Other drugs for the treatment of DKD (Finerenone, Keluoxin capsule, Qizhi Yishen capsule, SGLT2i drugs, GLP-1 drugs, etc.), b. Calcium oxybenzenesulfonate for the treatment of diabetic retinopathy, c. Chinese patent medicine, Chinese medicine decoction, formula granule and other Chinese medicine preparations with the same composition or function indications, d. Tripterygium wilfordii related preparations, Huangkui capsule - Patients who need to take antiplatelet drugs, the dose was stable for less than 1 month - Serious diseases of other systemic systems that may affect the judgment of efficacy and safety - A history of alcohol or drug abuse with a combination of mental illness and poor control - Allergic to the experimental drug or its ingredients - Women who are pregnant or breastfeeding, or who have a need to have children during the trial - Participating in other clinical studies and taking investigational drugs from other studies within 3 months prior to screening - The investigator deems that the patient is not suitable to participate in the study

Study Design


Intervention

Drug:
Qishen Yiqi Dripping Pills placebo 3 bags
Qishen Yiqi Dripping Pills placebo contain Qishen Yiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
Low dose Qishen Yiqi Dripping Pills 3 bags
Low dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 2 bags(0.52g dripping pills per bag) and Qishen Yiqi dripping pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
High dose Qishen Yiqi Dripping Pills 3 bags
High dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks

Locations

Country Name City State
China Dongzhimen Hospital of Beijing University of Chinese Medicine Beijing Beijing
China Xiyuan Hospital of China Academy of Chinese Medical Sciences Beijing Beijing
China The First Hospital of Hunan University of Chinese Medicine Changsha Hunan
China West China Hospital of Sichuan University Chengdu Sichuan
China The Affiliated TCM Hospital of Guangzhou Medical University Guangzhou Guangdong
China Heilongjiang Academy of Traditional Chinese Medicine (Heilongjiang Provincial Hospital of Traditional Chinese Medicine) Ha'erbin Heilongjiang
China Hangzhou hospital of traditional Chinese medicine Hangzhou Zhejiang
China The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang
China Kaifeng Hospital of Traditional Chinese Medicine Kaifeng Henan
China Luoyang Third People's Hospital Luoyang Henan
China Sanmenxia Central Hospital Sanmenxia Henan
China Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine Shanghai Shanghai
China Shanghai Sixth People's Hospital Shanghai Shanghai
China Hebei Province Hospital of Traditional Chinese Medicine Shijiazhuang Hebei
China First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin Tianjin
China Shananxi Province Hospital of Traditional Chinese Medicine Xi'an Shananxi

Sponsors (1)

Lead Sponsor Collaborator
Tasly Pharmaceutical Group Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in ß2-MG. Change in ß2-MG from baseline to weeks 4, 8 and 12. Baseline to weeks 4, 8 and 12
Other Change in Cys-C. Change in Cys-C from baseline to weeks 4, 8 and 12. Baseline to weeks 4, 8 and 12
Other Change in PCX. Change in PCX from baseline to week 12. Baseline to week 12
Other Change in MCP-1. Change in MCP-1 from baseline to week 12. Baseline to week 12
Primary Change in UACR(urinary albumin ? to ? creatinine ratio). Change in UACR from baseline to weeks 4, 8 and 12. Baseline to weeks 4, 8 and 12
Secondary Ratio of subjects with UACR returned to normal. Ratio of subjects with UACR returned to normal at weeks 4, 8 and 12. Baseline to weeks 4, 8 and 12
Secondary Ratio of subjects with UACR decrease of more than 30% from baseline. Ratio of subjects with UACR decrease of more than 30% from baseline at weeks 4, 8 and 12. Baseline to weeks 4, 8 and 12
Secondary Ratio of subjects from microalbuminuria stage to macroalbuminuria Ratio of subjects from microalbuminuria stage to macroalbuminuria at weeks 4, 8 and 12. Baseline to weeks 4, 8 and 12
Secondary Change in eGFR(estimated glomerular filtration rate). Change in eGFR from baseline to weeks 4, 8 and 12. Baseline to weeks 4, 8 and 12
Secondary Change in Traditional Chinese Medicine Syndrome Score Change in Traditional Chinese Medicine Syndrome Score from baseline to weeks 4, 8 and 12. There were 9 clinical primary symptoms, 7 clinical secondary symptoms, tongue picture and pulse condition evaluated as TCM symptoms, which was defined as TCM syndrome score. The standard of TCM primary symptoms and secondary symptoms scored as without 0, light 2, medium 4, heavy 6 points. Tongue picture and pulse condition did not count. Baseline to weeks 4, 8 and 12
Secondary TCM syndrome Number and ratio of subjects with Clinical recovery, obvious effect, effective or ineffective in curative effect of TCM syndrome at weeks 4, 8 and 12. Baseline to weeks 4, 8 and 12
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Not yet recruiting NCT06120569 - Evaluate the Role of Soleus Muscle Exercise in Glycaemic Control in Diabetic Kidney Disease Patients N/A
Completed NCT02545049 - Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease Phase 3
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Active, not recruiting NCT06176599 - Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis N/A
Recruiting NCT03716401 - Prognostic Imaging Biomarkers for Diabetic Kidney Disease
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Completed NCT01377688 - Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes N/A
Active, not recruiting NCT05514548 - Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease Phase 2
Recruiting NCT05507892 - Renal Mechanism of SGLT2 Inhibition Phase 2
Not yet recruiting NCT05514184 - Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease N/A
Not yet recruiting NCT06049550 - The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
Active, not recruiting NCT04589351 - Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe Phase 3
Active, not recruiting NCT04531163 - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy Phase 2/Phase 3
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Suspended NCT01878045 - Mechanisms of Diabetic Kidney Disease in American Indians
Completed NCT03627715 - Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan Phase 2